What pharmacology teaches us about the pathophysiology of obsessive-compulsive disorder

Revista Brasileira de Psiquiatria

Donatella Marazziti¹  Elena Di Nasso¹ 

[1] ,Universidade de Pisa Farmacologia e Biotecnologie Dipartimento di Psichiatria,Itália

关键词: Obsessive-compulsive disorder;    Serotonergic drugs;    Serotonin reuptake inhibitors;    Psychopharmacology;    Serotonin receptors;    Signal transduction;    Transtorno obsessivo-compulsivo;    Agentes serotoninérgicos;    Inibidores da captação de serotonina;    Psicofarmacologia;    Receptores de serotonina;    Transdução de sinal;   

DOI  :  10.1590/S1516-44462000000400009

来源: SciELO

【 摘 要 】

Once considered rare and resistant to treatments, obsessive-compulsive disorders (OCD) has now emerged as one the most common psychiatric conditions, with a lifetime prevalence of about 2.5 %, and as a major cause of long-term disability to patients and their families. The treatment of OCD has changed dramatically over the last decade following the introduction of selective serotonin (5-HT) reuptake inhibitors (SSRIs), such as fluoxetine, fluvoxamine, paroxetine, sertraline, citalopram, which provide symptom remission in about 60% of the patients. OCD is unique in the response to serotonergic agents and it has been clearly demonstrated that non-serotonergic antidepressants such as desipramine have no effect. The specific response of OCD patients to SSRIs has emphasized the possible role of the main target of these drugs, namely the 5-HT system, in the pathophysiology of the disorder. If the role of 5-HT in OCD is not questionable, future studies should be directed towards the elucidation of the 5-HT receptor subtypes involved, of the second messengers transducing the signal, as well as of the interactions between 5-HT and the other neurotransmitters.

【 授权许可】

CC BY-NC   
 All the contents of this journal, except where otherwise noted, is licensed under a Creative Commons Attribution License